{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:13:10Z","timestamp":1791313990010,"version":"4.3.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clinre.2023.102148","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T21:25:02Z","timestamp":1685049902000},"page":"102148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic hepatitis delta cirrhosis cured by adapting PEG-IFN\u03b1-2a\u00a0+\u00a0tenofovir disoproxil fumarate treatment duration until HBsAg loss"],"prefix":"10.1016","volume":"47","author":[{"given":"L.","family":"Yaici","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gatouillat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Andreoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"N'Guyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hentzien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gordien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bani-Sadr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinre.2023.102148_bib0001","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2023.102148_bib0002","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J Viral Hepat"},{"issue":"S1","key":"10.1016\/j.clinre.2023.102148_bib0003","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/liv.14356","article-title":"Future treatments for hepatitis delta virus infection","volume":"40","author":"Asselah","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.clinre.2023.102148_bib0004","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","article-title":"Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development","volume":"73","author":"Tout","year":"2020","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2023.102148_bib0005","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.clinre.2023.102148_bib0006","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1080\/00325481.2016.1175310","article-title":"Comparison of the efficacy of 12 months and longer courses of interferon therapy for the treatment of chronic delta hepatitis: a retrospective cohort study","volume":"128","author":"Soyer","year":"2016","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.clinre.2023.102148_bib0007","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long-term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.clinre.2023.102148_bib0008","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/apt.16408","article-title":"Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy","volume":"54","author":"Hercun","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.clinre.2023.102148_bib0009","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.jhep.2012.12.019","article-title":"Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta","volume":"58","author":"Ouzan","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2023.102148_bib0010","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/j.clinre.2013.01.002","article-title":"Resolution of chronic hepatitis delta infection after five years of peginterferon\u2013adefovir: lessons from a case report","volume":"37","author":"Brichler","year":"2013","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinre.2023.102148_bib0011","unstructured":"Sandmann L., Wedemeyer H. Interferon-based treatment of chronic hepatitis D. Liver Int. 2022 Sep 2;liv.15410."},{"issue":"12","key":"10.1016\/j.clinre.2023.102148_bib0012","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","article-title":"Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon Alfa-2a: week 120 analysis","volume":"63","author":"Ahn","year":"2018","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.clinre.2023.102148_bib0013","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/apt.16945","article-title":"Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-results of a \u2018real world\u2019 study","volume":"56","author":"Jachs","year":"2022","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740123000736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:36:04Z","timestamp":1761896164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740123000736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2210740123000736"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102148","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic hepatitis delta cirrhosis cured by adapting PEG-IFN\u03b1-2a\u00a0+\u00a0tenofovir disoproxil fumarate treatment duration until HBsAg loss","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2023.102148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102148"}}